
OCRL1 Peptide

Subcategory: Synthetic Peptide, Blocking Peptide

Cat. No.: 350539

Unit: 0.1 mg

Description:

Inositol polyphosphate 5-phosphatase (OCRL1) converts phosphatidylinositol 4,5-bisphosphate to phosphatidylinositol 4-phosphate. The enzyme also converts inositol 1,4,5-trisphosphate to inositol 1,4-bisphosphate and inositol 1,3,4,5-tetrakisphosphate to inositol 1,3,4-trisphosphate. The enzyme is involved in lysosomal membrane trafficking by regulating the specific pool of phosphatidylinositol 4,5-bisphosphate that is associated with lysosomes. Defects in OCRL1 are the cause of Lowe syndrome, a multisystem disorder affecting eyes, nervous system and kidney, and Dent disease type 2, a renal disease.

Format: Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.

Alternate Names: Inositol polyphosphate 5-phosphatase OCRL-1; Lowe oculocerebrorenal syndrome protein; OCRL; INPP5F

Accession No.: Q01968

MW: 1988.2 g/mol

Sequence: The synthetic peptide used to raise the antibody Cat. No. 200177 is selected from a sequence within the C-term region of human OCRL1. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.

Composition: C79H138N30O26S2

Purity: Purity > 80% by HPLC

Solubility: Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.

Storage: Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.

For research use only, not for diagnostic or therapeutic procedures.